Search

Your search keyword '"Reti, Marienn"' showing total 26 results
Start Over Author "Reti, Marienn"
26 results on '"Reti, Marienn"'

4. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura

Author

Velásquez Pereira, Leydi Carolina, Roose, Elien, Graça, Nuno A.G., Sinkovits, György, Kangro, Kadri, Joly, Bérangère S., Tellier, Edwige, Kaplanski, Gilles, Falter, Tanja, Von Auer, Charis, Rossmann, Heidi, Feys, Hendrik B., Reti, Marienn, Prohászka, Zoltán, Lämmle, Bernhard, Voorberg, Jan, Coppo, Paul, Veyradier, Agnès, De Meyer, Simon F., Männik, Andres, and Vanhoorelbeke, Karen

Published
2021
Full Text
View/download PDF

5. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Author

Roose, Elien, Schelpe, An-Sofie, Tellier, Edwige, Sinkovits, György, Joly, Bérangère S., Dekimpe, Charlotte, Kaplanski, Gilles, Le Besnerais, Maelle, Mancini, Ilaria, Falter, Tanja, Von Auer, Charis, Feys, Hendrik B., Reti, Marienn, Rossmann, Heidi, Vandenbulcke, Aline, Pareyn, Inge, Voorberg, Jan, Greinacher, Andreas, Benhamou, Ygal, Deckmyn, Hans, Fijnheer, Rob, Prohászka, Zoltan, Peyvandi, Flora, Lämmle, Bernhard, Coppo, Paul, De Meyer, Simon F., Veyradier, Agnès, and Vanhoorelbeke, Karen

Published
2020
Full Text
View/download PDF

6. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Author

Cataland, Spero R., Coppo, Paul, Scully, Marie, Lämmle, Bernhard, Alberio, Lorenzo, Antun, Ana, Ay, Cihan, Agosti, Pasquale, Azoulay, Elie, Baker, Ross, Benhamou, Ygal, Boechat, Tiago, Brinkkötter, Paul, Chaturvedi, Shruti, Crawley, James, De Cristofaro, Raimondo, Garma, Julio del Río, Dutt, Tina, De Groot, Rens, Rubia, Javier de la, Falter, Tanja, Farias, João, Friedman, Kenneth, Fujimura, Yoshihiro, Gavriilaki, Eleni, George, James N., Graça, Nuno A. G., Hassenpflug, Wolf-Achim, Izquierdo, Cristina Pascual, Joly-Laffargue, Bérangère, Kentouche, Karim, Knoebl, Paul, Kokame, Koichi, Hovinga, Johanna Kremer, Kühne, Lucas, Kyrle, Paul, Lester, Will, Mancini, Ilaria, Masias, Camila, Matsumoto, Masanori, Mazepa, Marshall, Miesbach, Wolfgang, Metjian, Ara, Mingot-Castellano, Maria-Eva, Miyata, Toshiyuki, Moake, Joel, Muia, Joshua, Patriquin, Chris, Pavenski, Katerina, Prohaszka, Zoltan, Peyvandi, Flora, Reti, Marienn, Rossmann, Heidi, Sakai, Kazuya, Sarode, Ravi, Schneppenheim, Reinhard, Schraner, Marissa, Singh, Deepak, Sinkovits, György, Stubbs, Matthew, Studt, Jan-Dirk, Sukumar, Senthil, Thomas, Mari, Tóth, Andor, Vanhoorelbeke, Karen, Veyradier, Agnes, Völker, Linus, Sophie von Krogh, Anne, Voorberg, Jan, Waage, Anders, Westwood, JP, Wood, Erica, Yagi, Hideo, and Zheng, X. Long

Abstract

[Display omitted]

Published
2024
Full Text
View/download PDF

7. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Author

Alberio, Lorenzo, Antun, Ana, Ay, Cihan, Agosti, Pasquale, Azoulay, Elie, Baker, Ross, Benhamou, Ygal, Boechat, Tiago, Brinkkötter, Paul, Chaturvedi, Shruti, Crawley, James, De Cristofaro, Raimondo, Garma, Julio del Río, Dutt, Tina, De Groot, Rens, Rubia, Javier de la, Falter, Tanja, Farias, João, Friedman, Kenneth, Fujimura, Yoshihiro, Gavriilaki, Eleni, George, James N., Graça, Nuno A. G., Hassenpflug, Wolf-Achim, Izquierdo, Cristina Pascual, Joly-Laffargue, Bérangère, Kentouche, Karim, Knoebl, Paul, Kokame, Koichi, Hovinga, Johanna Kremer, Kühne, Lucas, Kyrle, Paul, Lester, Will, Mancini, Ilaria, Masias, Camila, Matsumoto, Masanori, Mazepa, Marshall, Miesbach, Wolfgang, Metjian, Ara, Mingot-Castellano, Maria-Eva, Miyata, Toshiyuki, Moake, Joel, Muia, Joshua, Patriquin, Chris, Pavenski, Katerina, Prohaszka, Zoltan, Peyvandi, Flora, Reti, Marienn, Rossmann, Heidi, Sakai, Kazuya, Sarode, Ravi, Schneppenheim, Reinhard, Schraner, Marissa, Singh, Deepak, Sinkovits, György, Stubbs, Matthew, Studt, Jan-Dirk, Sukumar, Senthil, Thomas, Mari, Tóth, Andor, Vanhoorelbeke, Karen, Veyradier, Agnes, Völker, Linus, Sophie von Krogh, Anne, Voorberg, Jan, Waage, Anders, Westwood, JP, Wood, Erica, Yagi, Hideo, Zheng, X. Long, Cataland, Spero R., Coppo, Paul, Scully, Marie, and Lämmle, Bernhard

Published
2024
Full Text
View/download PDF

11. Safety and performance of the S pectra O ptia apheresis system for white blood cell depletion in patients with elevated white blood cell counts

Author

Lopert, Pamela, primary, Abdelrahman, Sohair, additional, Graybill, Christopher A., additional, Rhodes, Jack, additional, Dierickx, Daan, additional, Schäfer, Richard, additional, Reti, Marienn, additional, Wu, Depei, additional, Hu, Yu, additional, Huang, Fen, additional, Hu, Jianda, additional, He, Pengcheng, additional, Liu, Ligen, additional, Li, Ming, additional, Zhang, Xuejun, additional, and Bill, Jerry, additional

Published
2023
Full Text
View/download PDF

13. Safety and performance of the Spectra Optia apheresis system for white blood cell depletion in patients with elevated white blood cell counts.

Author

Lopert, Pamela, Abdelrahman, Sohair, Graybill, Christopher A., Rhodes, Jack, Dierickx, Daan, Schäfer, Richard, Reti, Marienn, Wu, Depei, Hu, Yu, Huang, Fen, Hu, Jianda, He, Pengcheng, Liu, Ligen, Li, Ming, Zhang, Xuejun, and Bill, Jerry

Subjects
LEUCOCYTES, LEUKOCYTE count
Abstract

Background: For the past 30 years, white blood cell depletion (WBCD) or leukocytapheresis has been conducted to rapidly reduce excessive circulating white blood cell (WBC) concentrations in patients at risk for or with symptoms of leukostasis due to hyperleukocytosis. The goal of leukocytapheresis is to prevent or treat acute complications from leukostasis, thereby enabling patients to receive potentially curative chemotherapy. Methods: This report details the results from a retrospective and a prospective clinical study conducted in the European Union and the People's Republic of China, which assessed the use of the Spectra Optia Apheresis System for leukocytapheresis in patients with hyperleukocytosis. The primary objective of both studies was to the assess the safety and performance of the WBCD procedure in patients with elevated WBC counts. Results: Data were collected from 72 participants completing 87 WBCD procedures. The mean percent change in participant WBC counts post‐procedure was 50.3 ± 21.2% and the collection efficiency (CE1) of the WBCD procedures was 53.7 ± 19.8%. Sixty‐one participants (95.3%) experienced a total of 279 adverse events (AEs) with the majority of the AEs related to post‐procedure changes in laboratory values, which is an anticipated AE in this patient population. Conclusion: The data collected within these studies indicate that the WBCD procedure is safe and well tolerated in patients with hyperleukocytosis as evaluated by percent decrease in WBC count, CE1, and AE incidence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Author

Coppo, PAUL, Bubenheim, Michaël, Benhamou, Ygal, Voelker, Linus A., Brinkkoetter, Paul T., Kühne, Lucas, Knoebl, Paul N., Mingot, Maria Eva, Pascual Izquierdo, Maria Cristina, De La Rubia, Javier, Del Rio Garma, Julio, Chaturvedi, Shruti, Masias, Camila, Mazepa, Marshall, Zheng, X. Long, Sinkovits, Gyorgy, Reti, Marienn, Patriquin, Christopher J., Pavenski, Katerina, Boechat, Tiago, Farias, Joao, Ribeiro, Eduardo Flavio Oliveira, de Andrade, Michaela Larissa Lobo, Veyradier, Agnès, Joly, Bérangère, Sr., Bouzid, Raïda, Sakai, Kazuya, Matsumoto, Masanori, Mancini, Ilaria, Agosti, Pasquale, Peyvandi, Flora, Stubbs, Matthew James, Hmaid, Amjad, Sharif, Sobia, Dutt, Tina, Cataland, Spero, Lammle, Bernhard, and Scully, Marie

Published
2023
Full Text
View/download PDF

18. Dissection of Subclonal Evolution by Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Author

Gángó, Ambrus, Alpár, Donát, Galik, Bence, Marosvári, Dóra, Kiss, Richárd, Fésüs, Viktória, Aczél, Dóra, Nagy, Noémi, Nagy, Ákos, Krizsán, Szilvia, Reiniger, Lilla, Farkas, Péter, Kozma, András, Ádám, Emma, Tasnády, Szabolcs, Réti, Marienn, Matolcsy, András, Gyenesei, Attila, Mátrai, Zoltán, and Bödör, Csaba

Published
2019
Full Text
View/download PDF

20. A Novel, Closed-Line Mini Extracorporeal Photopheresis (ECP) Technique Using the Therakos TMCellEx TMPhotopheresis System, Developed for Patients with Contraindications Against Conventional ECP Therapy

Author

Várkonyi, Andrea, Kállay, Krisztián, Dobos, Katalin, Tasnády, Szabolcs, Reményi, Péter, and Reti, Marienn

Abstract

Introduction:Conventional ECP has proven efficacy for treating several diseases, most significantly steroid-refractory chronic GVHD. Unfortunately, body weight and sufficient venous access limit the availability of this treatment modality. Children, in particular, usually have limited access to ECP. A simplified mini buffy coat ECP technique that allows treating small children and patients with apheresis contraindications has been tested in selected cases during the last 20 years. However, this method relies on an open-line system that requires a longer time and a cell processing laboratory, making this approach challenging.

Published
2023
Full Text
View/download PDF

21. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late

Author

Basak, Grzegorz W., Mikala, Gabor, Koristek, Zdenek, Jaksic, Ozren, Basic-Kinda, Sandra, Cegledi, Andrea, Reti, Marienn, Masszi, Tamas, Mayer, Jiri, Giebel, Sebastian, Huebel, Kai, Labar, Boris, Wiktor-Jedrzejczak, Wieslaw, Basak, Grzegorz W., Mikala, Gabor, Koristek, Zdenek, Jaksic, Ozren, Basic-Kinda, Sandra, Cegledi, Andrea, Reti, Marienn, Masszi, Tamas, Mayer, Jiri, Giebel, Sebastian, Huebel, Kai, Labar, Boris, and Wiktor-Jedrzejczak, Wieslaw

Abstract

Plerixafor can rescue the outcome of failing chemotherapy-based stem cell mobilization. However, the optimal time for plerixafor injection in this setting has not been determined. This was investigated by retrospective analysis of data from 48 mobilizations with plerixafor, chemotherapy, and granulocyte-colony stimulating factor (G-CSF). The required yield of 2.0 x 10(6) CD34+ cells/kg was collected from 71% of patients; the median total yield was 4.1 x 10(6) CD34+ cells/kg. Patients to whom plerixafor was administered late (>= 15 days) after chemotherapy, after a long duration (>= 13 days) of treatment with G-CSF, or when the white blood cell count was high (>= 20 x 10(9)/L) were mobilized as efficiently as other patients. Plerixafor was shown to rescue mobilizations at a comparable rate in patients with critically low levels of peripheral blood CD34+ cells (53/mL) and those with higher concentrations. These data suggest that late administration of plerixafor in the course of chemotherapy-based mobilization does not contribute to the failure of this strategy.

Published
2011

23. Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy

Author

Vertesaljai, Marton, primary, Piroth, Zsolt, additional, Fontos, Geza, additional, Andreka, Gyorgy, additional, Font, Gusztav, additional, Szantho, Gergely, additional, Lueff, Sandor, additional, Reti, Marienn, additional, Masszi, Tamas, additional, Ablonczy, Laszlo, additional, Juhasz, Eszter D., additional, Simor, Tamas, additional, Turner, Mark S., additional, and Andreka, Peter, additional

Published
2007
Full Text
View/download PDF

26. Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.

Author

Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M, Reti M, Takacs P, Heteren PV, Zadoyan G, Holtkamp S, Overstijns T, Miltenyi S, Remenyi P, and Nagy G

Subjects
Humans, Treatment Outcome, Remission Induction, Middle Aged, Female, Receptors, Chimeric Antigen therapeutic use, Receptors, Chimeric Antigen immunology, Male, Lymphoma, Large B-Cell, Diffuse therapy, Lymphoma, Large B-Cell, Diffuse diagnosis, Arthritis, Rheumatoid therapy, Antigens, CD19 immunology, Immunotherapy, Adoptive methods, Immunotherapy, Adoptive adverse effects, Antigens, CD20 immunology
Abstract

We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy., Competing Interests: Competing interests: DS, PT, PvH, GZ, SH, TO and SM are employees of Miltenyi Biomedicine GmbH. GN received speaker honoraria from Astra Zeneca, AbbVie, GSK, Lilly, Pfizer, MSD, Roche, Miltenyi, SOBI and Swixx., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results